Opko Health, Inc.

Good day, ladies and gentlemen, and welcome to Opco Health, Inc. Third Quarter 2021 Financial Results Conference Call. At this time, all participant lines are in the listen-only mode. Later, we will conduct a question-and-answer session, and instructions will be given at that time. To ask a question, you will need to press star, then 1 on your telephone. As a reminder, this call is being recorded. If anyone should require operator assistance, please press star, then 0. I would now like to hand the conference over to your host today, Yvonne Briggs, please go ahead.

Thank you, Sarah, and good afternoon. This is Yvonne Briggs with LHA. Thank you all for joining today's call to discuss Opco Health's financial results for the third quarter of 2021. I'd like to remind you that any statements made during this call by management, other than statements of historical fact, will be considered forward-looking and, as such, will be subject to risks and uncertainties that could materially affect the company's expected results. Those forward-looking statements include, without limitation, the various risks described in the company's SEC filings, including the annual report on Form 10-K for the year ended December 31, 2020, and in subsequently filed SEC reports. Importantly, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, today, October 28, 2021, except as required by law OPCO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Before we begin, let me review the format of today's call. Dr. Philip Frost, Chairman and Chief Executive Officer, will open the call. Steve Rubin, OPCO's Executive Vice President, will provide a business update and pipeline review. And then Dr. John Cohen will discuss bioreference laboratories. After that, Adam Logel, Opco's CFO, will review the company's third quarter financial results, and then we'll open the call to questions. Now I'd like to turn the call over to Dr. Frost.

I'll start with our pharmaceutical business. Start over? Yep.